Pilot study of cytokines in emergency department patients with systemic inflammatory response syndrome

Academic Emergency Medicine

Volumn 4, Issue 7, 1997, Pages 684-688

  Terregino, Carol A ^a,c   Quinn, James V ^b   Slotman, Gus J ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Department of Surgery ^*

^c University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School at Camden   (United States)

Author keywords

Cytokines; Eicosanoids; Emergency medicine; Interleukin 1; Interleukin 6; Sepsis; SIRS; Tumor necrosis factor

Indexed keywords

ICOSANOID; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; SEPSIS;

EID: 0030757412     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1553-2712.1997.tb03760.x     Document Type: Article

References (30)

1. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA. 1995; 273:934-41.
2. Fisher CJ Jr, Dhainault JF, Pribble JP, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of sepsis syndrome. Result of a randomized, double-blind placebo-controlled trial. Phase III rh IL-1 ra Sepsis Study Group. JAMA. 1994; 27:1836-43.
3. Casey LR, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993; 119:771-8.
4. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992; 101:1644-55.
5. Dinarello CA, Cannon JG. Cytokine measurements in septic shock. Ann Intern Med. 1993; 15:853-4.
6. Goldie AS, Fearon KC, Ross JA, et al. Natural cytokine antagonists and the endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA. 1995; 274:172-7.
7. Drost AC, Burleson DG, Cioffi WG, Mason AD, Pruitt BA. Plasma cytokines after thermal injury and their relationship to infection. Ann Surg. 1993; 218:74-8.
8. Groll AH, Meiser A, Weise M, et al. Interleukin 6 as early mediator in neonatal sepsis. Pediatr Infect Dis J. 1992; 11:496-8.
9. Friedland JS, Suputtamongkol Y, Remick DG, et al. Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect Immun. 1992; 60:2402-8.
10. Moscovitz H, Shofer F, Mignott H, Behrman A, Kilpatrick L. Plasma cytokine determinations in emergency department patients as a predictor of bacteremia and infectious disease severity. Crit Care Med. 1994; 22:1102-7.
11. Teti G, Mancuso G, Tomasello F, Chiofalo MS. Production of tumor necrosis factor alpha and interleukin-6 in mice infected with group B streptococci. Circ Shock. 1992; 38:138-44.
12. Dinarella CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991; 77:1627-52.
13. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991; 115: 457-69.
14. van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense. Shock. 1995; 3:1-12.
15. Martin C, Saux P, Mege JL, Perrin G, Papazian L, Govin F. Prognostic values of serum cytokines in septic shock. Intensive Care Med. 1994; 20:272-7.
16. Walsh CJ, Sugerman HJ, Mullen PG, et al. Monoclonal antibody to tumor necrosis factor a attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg. 1992; 127:138-45.
17. McCrory D, Weir C, Halliday I, et al. The reliability of endotoxin and cytokine measurements in polytrauma patients and their relationship to the development of sepsis [letter]. Intensive Care Med. 1994; 20: 461.
18. Pruitt JH, Copeland EM 3rd, Moldower LL. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock. Shock. 1995; 3:235-51.
19. Hazelzet JA, van der Voort E, Lindermans J, ter Heerdt PG, Neijens HJ. Relation between cytokines and routine laboratory data in children with septic shock and purpura. Intensive Care Med. 1994; 20:371-4.
20. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med. 1989; 17:975-8.
21. Johnson J, Meyrick B, Jesmok G, Bringham KL. Human recombinant tumor necrosis factor mimics endotoxemia in awake sheep. J Appl Physiol. 1989; 66:1448-54.
22. Korn JH, Downie E, Roth GJ, Ho SY. Synergy of interleukin 1 (IL-1) with arachidonic acid and A23187 in stimulating PGE synthesis in human fibroblast cyclooxygenase. Clin Immunol Immunopathol. 1989; 50:196-204.
23. 4 in sepsis. Res Commun Chem Pathol Pharmacol. 1994; 83:151-6.
24. Meyers AK, Robey JW, Price RM. Relationships between tumor necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. Br J Pharmacol. 1990; 99:499-502.
25. Kettlhut IC, Fiers W, Goldberg AL. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors [abstract]. Proc Acad Natl Sci U S A. 1987; 84:4273.
26. Müllen PG, Windsor AC, Walsh CJ, et al. Combined ibuprofen and monoclonal antibody to tumor necrosis factor-alpha attenuates hemodynamic dysfunction and sepsis induced acute lung injury. J Trauma. 1993; 34:612-20.
27. Donnelly TJ, Meade P, Jagels M, et al. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med. 1994; 22: 768-75.
28. Engervall P, Andersson B, Bjorkholm M. Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. Br J Haematol. 1995; 91:838-45.
29. Ostermann H, Rothenburger M, Mesters RM, van de Loo J, Kienast J. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol. 1994; 88: 332-7.
30. Knaus WA, Wagner DP, Draper EA. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991; 100:1619-36.